Trials / Recruiting
RecruitingNCT06664021
Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma
Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma：A Prospective, Multicenter, Phase II Clinical Study
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Anhui Provincial Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Evaluating the efficacy and safety of treatment with Tislelizumab in combination with S-1 in patients with high-risk recurrent intrahepatic cholangiocarcinoma after radical surgery
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab combined with S-1 | Tislelizumab：200mg q3w iv , lasts for one year. S-1：40mg, 50mg, or 60mg orally twice daily for 4 weeks, depending on body surface area, followed by 2 weeks of rest，lasts four cycles. |
Timeline
- Start date
- 2024-11-16
- Primary completion
- 2026-12-30
- Completion
- 2026-12-30
- First posted
- 2024-10-29
- Last updated
- 2025-01-10
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06664021. Inclusion in this directory is not an endorsement.